MarketPulse

pipeline progress

2 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Novo Nordisk Bets on OpenAI Partnership to Reshape Drug Development Economics

Novo Nordisk partners with OpenAI to accelerate drug discovery via AI. Long-term benefits possible, but near-term headwinds from competition and clinical setbacks persist.
LLYNVOclinical trialsdiabetes
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Three Sub-$50 Healthcare Stocks Poised for Growth in Pharma, Oncology Sectors

Three healthcare stocks under $50 offer distinct value: Pfizer at $27.45 with 9x P/E and strong oncology pipeline; Novo Nordisk at $38.43 capitalizing on weight-loss drugs; Exelixis at $41.80 with proven oncology franchise.
PFENVOEXELvaluationbiotech